nach oben

Medical Oncology

Erschienen in:

01.04.2023 | Original Paper

PI3K/AKT/mTOR inhibitors as potential extracellular matrix modulators for targeting EMT subtype gastric tumors

verfasst von: Ponmathi Panneerpandian, Kumaresan Ganesan

Erschienen in: Medical Oncology | Ausgabe 4/2023

Einloggen, um Zugang zu erhalten

Abstract

Targeting the extracellular matrix (ECM) is considered as a promising strategy in cancer therapeutics. This study was designed to identify the potential ECM modulators for gastric cancer therapeutics. Exploration of the expression profiles of gastric tumors revealed the elevated expression of ECM genes in gastric tumor tissues compared to the adjacent normal tissues with increased expression in diffuse subtype gastric tumors and specifically in epithelial to mesenchymal transition (EMT) molecular subtype tumors. Consensus ECM gene set was derived from the expression profiles of gastric tumors. The correlative analysis was performed between the expression pattern of the ECM gene set and the drug sensitivity pattern of a panel of drugs across gastric cancer cell lines. Negative correlation between the expression of ECM genes and sensitivity of a number of drugs targeting PI3K/mTOR signaling, chromatin histone acetylation and ABL signaling was observed. These pathways are known for their role in cell-mediated adhesion, differentiation and epithelial to mesenchymal transition. The current results reveal the possibility of using PI3K/AKT/mTOR modulators for targeted gastric cancer therapy in patients with dysregulated ECM.

Nur mit Berechtigung zugänglich

Andreuzzi E, Capuano A, Poletto E, et al. Role of extracellular matrix in gastrointestinal cancer-associated angiogenesis. Int J Mol Sci. 2020;21:3686.CrossRefPubMedPubMedCentral

Henke E, Nandigama R, Ergün S. Extracellular matrix in the tumor microenvironment and its impact on cancer therapy. Front Mol Biosci. 2020;6:160.CrossRefPubMedPubMedCentral

Huang J, Zhang L, Wan D, et al. Extracellular matrix and its therapeutic potential for cancer treatment. Signal Transduct Target Ther. 2021;6:153.CrossRefPubMedPubMedCentral

Elgundi Z, Papanicolaou M, Major G, et al. Cancer metastasis: the role of the extracellular matrix and the heparan sulfate proteoglycan perlecan. Front Oncol. 2020;9:1482.CrossRefPubMedPubMedCentral

Bass AJ, Thorsson V, Shmulevich I, et al. Comprehensive molecular characterization of gastric adenocarcinoma. Nature. 2014;513:202–9. https://doi.org/10.1038/nature13480.CrossRef

Subramanian A, Tamayo P, Mootha VK, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA. 2005;102:15545–50. https://doi.org/10.1073/pnas.0506580102.CrossRefPubMedPubMedCentral

Shao X, Taha IN, Clauser KR, et al. MatrisomeDB: the ECM-protein knowledge database. Nucl Acids Res. 2020. https://doi.org/10.1093/nar/gkz849.CrossRefPubMedPubMedCentral

Levine DM, Haynor DR, Castle JC, et al. Pathway and gene-set activation measurement from mRNA expression data: the tissue distribution of human pathways. Genome Biol. 2006. https://doi.org/10.1186/gb-2006-7-10-r93.CrossRefPubMedPubMedCentral

Ooi CH, Ivanova T, Wu J, et al. Oncogenic pathway combinations predict clinical prognosis in gastric cancer. PLoS Genet. 2009. https://doi.org/10.1371/journal.pgen.1000676.CrossRefPubMedPubMedCentral

10.

Ashburner M, Ball CA, Blake JA, et al. Gene ontology: tool for the unification of biology. Nat Genet. 2000;25:25–9.CrossRefPubMedPubMedCentral

11.

Chen EY, Tan CM, Kou Y, et al. Enrichr: interactive and collaborative HTML5 gene list enrichment analysis tool. BMC Bioinform. 2013. https://doi.org/10.1186/1471-2105-14-128.CrossRef

12.

Szász AM, Lánczky A, Nagy Á et al (2016) Cross-validation of survival associated biomarkers in gastric cancer using transcriptomic data of 1065 patients. Oncotarget 7:49322–49333. https://doi.org/10.18632/oncotarget.10337

13.

Gotea V, Ovcharenko I. DiRE: identifying distant regulatory elements of co-expressed genes. Nucl Acids Res. 2008. https://doi.org/10.1093/nar/gkn300.CrossRefPubMedPubMedCentral

14.

Donaldson JG. Immunofluorescence staining. Curr Protoc Cell Biol. 2015;69:431–7. https://doi.org/10.1002/0471143030.cb0403s69.CrossRef

15.

Tamilzhalagan S, Rathinam D, Ganesan K. Amplified 7q21-22 gene MCM7 and its intronic miR-25 suppress COL1A2 associated genes to sustain intestinal gastric cancer features. Mol Carcinog. 2017;56:1590–602. https://doi.org/10.1002/mc.22614.CrossRefPubMed

16.

Pickup MW, Mouw JK, Weaver VM (2014) The extracellular matrix modulates the hallmarks of cancer. EMBO Rep. https://doi.org/10.15252/embr.201439246

17.

Moreira AM, Pereira J, Melo S, et al. The extracellular matrix: an accomplice in gastric cancer development and progression. Cells. 2020;9:394.CrossRefPubMedPubMedCentral

18.

Jinawath N, Furukawa Y, Hasegawa S, et al. Comparison of gene-expression profiles between diffuse- and intestinal-type gastric cancers using a genome-wide cDNA microarray. Oncogene. 2004. https://doi.org/10.1038/sj.onc.1207886.CrossRefPubMed

19.

Yap YS, McPherson JR, Ong CK et al (2014) The NF1 gene revisited—from bench to bedside. Oncotarget. https://doi.org/10.18632/oncotarget.2194

20.

Yang W, Soares J, Greninger P, et al. Genomics of drug sensitivity in cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells. Nucl Acids Res. 2013. https://doi.org/10.1093/nar/gks1111.CrossRefPubMedPubMedCentral

21.

Barretina J, Caponigro G, Stransky N, et al. The cancer cell line encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature. 2012;483:603–7. https://doi.org/10.1038/nature11003.CrossRefPubMedPubMedCentral

22.

Malik R, Lelkes PI, Cukierman E. Biomechanical and biochemical remodeling of stromal extracellular matrix in cancer. Trends Biotechnol. 2015;33:230–6.CrossRefPubMedPubMedCentral

23.

Walker C, Mojares E, Del Río HA. Role of extracellular matrix in development and cancer progression. Int J Mol Sci. 2018;19:3028.CrossRefPubMedPubMedCentral

24.

Winkler J, Abisoye-Ogunniyan A, Metcalf KJ, Werb Z. Concepts of extracellular matrix remodelling in tumour progression and metastasis. Nat Commun. 2020;11:5120.CrossRefPubMedPubMedCentral

25.

Aktar R, Peiris M, Fikree A, et al. A novel role for the extracellular matrix glycoprotein-Tenascin-X in gastric function. J Physiol. 2019. https://doi.org/10.1113/JP277195.CrossRefPubMedPubMedCentral

26.

Li Z, Liu Z, Shao Z, et al. Identifying multiple collagen gene family members as potential gastric cancer biomarkers using integrated bioinformatics analysis. PeerJ. 2020. https://doi.org/10.7717/peerj.9123.CrossRefPubMedPubMedCentral

27.

Järveläinen H, Sainio A, Koulu M, et al. Extracellular matrix molecules: potential targets in pharmacotherapy. Pharmacol Rev. 2009;61:198–223.CrossRefPubMedPubMedCentral

28.

Holle AW, Young JL, Spatz JP. In vitro cancer cell-ECM interactions inform in vivo cancer treatment. Adv Drug Deliv Rev. 2016;97:270–9.CrossRefPubMed

29.

Harisi R, Jeney A. Extracellular matrix as target for antitumor therapy. Onco Targets Ther. 2015. https://doi.org/10.2147/OTT.S48883.CrossRefPubMedPubMedCentral

30.

Subrahmanyam N, Ghandehari H. Harnessing extracellular matrix biology for tumor drug delivery. J Pers Med. 2021;11:88.CrossRefPubMedPubMedCentral

31.

Nallanthighal S, Heiserman JP, Cheon DJ. The role of the extracellular matrix in cancer stemness. Front Cell Dev Biol. 2019;7:86.CrossRefPubMedPubMedCentral

32.

Morris JC, Tan AR, Olencki TE, et al. Phase I study of GC1008 (Fresolimumab): a human anti-transforming growth factor-beta (TGFβ) monoclonal antibody in patients with advanced malignant melanoma or renal cell carcinoma. PLoS ONE. 2014. https://doi.org/10.1371/journal.pone.0090353.CrossRefPubMedPubMedCentral

33.

Élez E, Kocáková I, Höhler T, et al. Abituzumab combined with cetuximab plus irinotecan versus cetuximab plus irinotecan alone for patients with KRAS wild-type metastatic colorectal cancer: the randomised phase I/II POSEIDON trial. Ann Oncol. 2015. https://doi.org/10.1093/annonc/mdu474.CrossRefPubMed

34.

Maden CH, Fairman D, Chalker M, et al. Safety, tolerability and pharmacokinetics of GSK3008348, a novel integrin αvβ6 inhibitor, in healthy participants. Eur J Clin Pharmacol. 2018. https://doi.org/10.1007/s00228-018-2435-3.CrossRefPubMedPubMedCentral

35.

Jang M, Koh I, Lee SJ, et al. Droplet-based microtumor model to assess cell-ECM interactions and drug resistance of gastric cancer cells. Sci Rep. 2017. https://doi.org/10.1038/srep41541.CrossRefPubMedPubMedCentral

Titel: PI3K/AKT/mTOR inhibitors as potential extracellular matrix modulators for targeting EMT subtype gastric tumors
verfasst von: Ponmathi Panneerpandian
Kumaresan Ganesan
Publikationsdatum: 01.04.2023
Verlag: Springer US
Erschienen in: Medical Oncology / Ausgabe 4/2023
Print ISSN: 1357-0560
Elektronische ISSN: 1559-131X
DOI: https://doi.org/10.1007/s12032-023-01984-0

Springer Medizin

PI3K/AKT/mTOR inhibitors as potential extracellular matrix modulators for targeting EMT subtype gastric tumors

Abstract

Neu im Fachgebiet Onkologie

Alphablocker schützt vor Miktionsproblemen nach der Biopsie

Antikörper-Wirkstoff-Konjugat hält solide Tumoren in Schach

Mammakarzinom: Senken Statine das krebsbedingte Sterberisiko?

Labor, CT-Anthropometrie zeigen Risiko für Pankreaskrebs

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2023

Nutrition care is an integral part of patient-centred medical care: a European consensus

RUNX2 promotes the suppression of osteoblast function and enhancement of osteoclast activity by multiple myeloma cells

Insights into ovarian cancer: chemo-diversity, dose depended toxicities and survival responses

ACADL suppresses PD-L1 expression to prevent cancer immune evasion by targeting Hippo/YAP signaling in lung adenocarcinoma

Role of epigenetics in OSCC: an understanding above genetics

Electrochemical therapy (EChT) of cancer tumor with an external anode, a way to achieve pathological complete response

Neu im Fachgebiet Onkologie

Alphablocker schützt vor Miktionsproblemen nach der Biopsie

Antikörper-Wirkstoff-Konjugat hält solide Tumoren in Schach

Mammakarzinom: Senken Statine das krebsbedingte Sterberisiko?

Labor, CT-Anthropometrie zeigen Risiko für Pankreaskrebs

Update Onkologie